Eli Lilly to collaborate with diabetes tech companies on insulin pen
pharmafile | May 10, 2021 | News story | Sales and Marketing | Eli Lilly, diabetes
Eli Lilly has signed strategic international agreements with four companies – Dexcom, Glooko, myDiabby Healthcare, and Roche – with the goal of integrating data and technology with their insulin pen products to help people with diabetes better manage their condition.
The companies involved in the collaboration have unique diabetes management platforms that can be integrated with two products from Eli Lilly, the Tempo Pen and Tempo Smart Button.
The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button – pending CE marking – attaches. Through these new agreements, the Tempo Smart Button will pair with software and/or medical devices offered by Dexcom, Glooko, myDiabby Healthcare and Roche, with its mySugr app, to facilitate the integration of personalised data and actionable insights.
Marie Schiller, vice president of product development for Connected Care and Insulins at Lilly, said: “Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
“By integrating data from the connected insulin pen solutions into widely used compatible software, including potential future collaborations, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection. These solutions may also help address psychological barriers like fear of hypoglycaemia that may negatively impact diabetes management.”
The companies involved in the collaboration will contribute the following:
- DexCom: Continuous glucose monitoring (CGM) products
- Glooko: Software platforms, Glooko and diasend, for the management of diabetes and other chronic conditions by collecting data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected scales, and activity trackers
- MyDiabby Healthcare: Software for healthcare providers to manage and help their patients with diabetes remotely through telemonitoring and tele consultation
- Roche Diabetes Care: Under the brands RocheDiabetes, Accu-Chek, and mySugr, Roche Diabetes Care is involved in glucose monitoring, insulin delivery systems and digital solutions
Around 4 million people in the UK and an estimated 463 million adults worldwidehave diabetes. Type 2 diabetes is the most common type internationally, accounting for an estimated 90 percent of all diabetes cases in the UK alone. Hypoglycemia is a common condition experienced by diabetes sufferers and is a result of poor insulin management, it can have a serious impact on an individual’s health.
Lilly aims to receive CE mark for the Tempo Smart Button later in 2021 and will launch the Tempo Pen and Tempo Smart Button in several international markets following this certification.
Kat Jenkins
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche shares data on novel solution for continuous glucose monitoring
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …
